Compare Eos Energy Enterprises Inc (EOSE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Eos Energy Enterprises Inc trades at $2.54 (market cap $1.01B), while State Street SPDR S&P Biotech ETF trades at $153.87 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 10× Eos Energy Enterprises Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EOSE | XBI | |
|---|---|---|
Market Cap | $1.01B | $10.11B |
Volume | 39,626,541 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $19.19 | $169.55 |
52-Week Low | $2.77 | $104.99 |
Typical Hold Time | 16 Days | 38 Days |
Enterprise Value | $1.34B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.575, down 16.94% in the last session, reflecting ongoing volatility despite positive business developments. The company shows rapid revenue growth with $214M projected for 2026 but faces significant profitability challenges with a -246.76% net income margin. Recent catalysts include an $87M Department of Energy loan advance and a major partnership with Google for a $350M West Virginia energy project announced September 2, 2026.
While analyst consensus remains cautiously optimistic with a $7.10 price target representing 176% upside, the stock carries substantial risk due to persistent losses and high debt-to-asset ratio of 91.87%. The technical picture is bearish with weak momentum, though oversold RSI levels may indicate potential for near-term bounce. Investment appeal hinges on successful execution of production scaling and path to profitability.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
